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Pepsin types and structure
Pepsins are aspartate proteases active in acidic conditions 
and are the major proteases in human gastric juice. 
Pepsins are therefore important in normal digestion of 
proteins and along with acid in the protection against 
ingested pathogenic organisms gaining a foothold in the 
gastrointestinal tract. The active enzyme is derived from 
its pro-enzyme pepsinogen which is secreted into the 
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lumen of the gastric glands from chief cells (peptic cells). 
Pepsinogens consist of two immunological groups PGI 
containing pepsinogens 1, 2 ,3, 4 and 5 and PGII containing 
pepsinogens 6 and 7 (1,2). Pepsinogen is a symmetrical 
molecule with N and C terminal lobes with a molecular 
weight between 40–42 K (3) and is stable up to pH values 
of 10 (4). However, when it is exposed to pH levels below 
5, which occurs in the gastric glands, an auto-catalytic 
activation occurs. This involves the removal of a section of 
the pesinogen’s N-terminal (5-7). The generated pepsins 
consist of 1, 2, 3a, 3b, 3c, 4, 5, 6, 7 and can be separated by 
anion exchange high performance liquid chromatography 
(HPLC) and agar gel electrophoresis (8,9). Pepsin 
7 isolated from gastric mucosa also referred to as a slow-
moving protease is an aspartate protease. However, it is not 
a pepsin but instead a cathepsin E which is an intracellular 
enzyme (10).
We present the following article in accordance with the 
Narrative Review reporting checklist (available at http://
dx.doi.org/10.21037/aoe-20-95).
Pepsin activation and function of activation 
peptides
The mechanism of activation by just a change in pH is 
well understood in human and porcine pepsin (5,11). 
The activation peptide, the N-terminal of the pepsinogen 
molecule which is cleaved off when pepsin is activated, has 
recently been shown to have antimicrobial properties (12). 
Human pepsinogen has a predicted amino acid sequence of 
373 amino acids (13). In human pepsin the cleaved peptide 
is 47 amino acids long and is generally released as 2 peptides 
generating an active enzyme with a molecular weight 34–37 
KD (5,14,15). The cleavage occurs in the region Leu23-
Lys24-Asp25-Phe26 but the full-length peptide can also 
be detected, resulting in the appearance of 5 potential 
peptides in gastric juice 1–23, 1–25, 24–47, 26–47 and 1–47 
(5). In order to test the antimicrobial properties of these 
Pane et al. expressed recombinant proteins in E. coli BL21 
(DE3) producing the full length 47 amino acid peptide, a 
1–25 and a 26–47 amino acid peptide. The only difference 
between these peptides and the original pepsinogen peptides 
is a proline at the N-terminal which was placed in the 
pepsinogen sequence to produce acid labile sequences and 
this proline is unlikely to affect any anti-microbial properties 
(16,17). Computational analysis was used to identify 
cryptic antimicrobial peptides (AMPs) based on amino acid 
composition, charge, and hydrophobicity of known AMPs. 
This analysis indicated that the pepsinogen peptides would 
have antimicrobial activity. The full-length peptide was 
shown to have a minimum inhibitory concentration (MIC) 
of ≤12.5 µM against a wide range of bacterium including E. 
coli, Pseudomonas’, and Staphylococcus’, but greater than 50 µM 
for Listeria.
The two shorter peptides performed worse but were 
still effective around 50 µM (Table 1). To determine if 
this effect also occurred at acidic conditions pertaining to 
the stomach the full-length peptide was tested at pH 3.5. 
Bacterial viability was measured as CFU/mL and Salmonella 
typhimurium which has resistance to low pH had ~50% 
survival after 45 minutes exposure to pH 3.5. When the 
full-length peptide was added this was reduced to ~20% (12).
The 1–25 peptide was also effective in preventing biofilm 
formation of Pseudomonas aeruginosa and Staphylococcus 
aureus. Finally, in a mouse model of Pseudomonas aeruginosa 
infection the full-length peptide showed 4 orders of 
magnitude reduction in CFU/mL and the two shorter 
peptides ~2 orders of magnitude (12).
These findings highlight that pepsin’s activation peptides 
generated from secreted pepsinogen may form an important 
Table 1 Antimicrobial activity of pepsinogen activation peptides
Bacterial species
Minimum inhibitory concentration (µM)
1–47 1–25 26–47
Escherichia coli 6.3 25 >50
Salmonella typhimurium 6.3 25 >50
Pseudomonas aeruginosa 6.3 25 25
Staphylococcus aureus 6.3 25 >50
Listeria monocytogenes >50 >50 >50
Data taken from Pane et al. (16).
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element of the antimicrobial barrier function of gastric 
juice. This may be particularly important in the case of 
microbial resistance to low pH. 
Pepsinogen and pepsin stability 
Unlike pepsinogen, pepsin is not stable at alkaline pH. 
When purified pepsin 3 was incubated over 24 hours at 37 ℃ 
with pH ranging from 2–8, when measuring at pH 2, 100% 
of activity could be recovered after the pre-incubation 
between pH 4–6.8 but no activity was recovered after pH 
7.0. The activity after pre-incubation at pH 2.0 shows only 
60% is recovered, not due to direct denaturation but as 
a result of pepsin auto-digestion. When this is repeated 
with human gastric juice pepsin activity is recoverable 
after incubation up to pH 7.5 but completely lost at pH 
8.0 (18). Studies by Johnston et al. (19) carrying out similar 
experiments with pepsin 3 showed no activity could be 
recovered after 24-hour incubation at pH 8.0. The upshot 
of these studies suggests that pepsin is irreversibly denatured 
at pH between 7.0 and 8.0. The reason for the differences 
in stability between pepsinogen and pepsin is the missing 
activation peptides, meaning that the C-terminal can refold 
but not the N-terminal (20-22). In considering activity, 
pepsin shows proteolytic activity up to pH 6.5 so at pH 6.5 
pepsin will have no activity but is still stable and can be re-
activated with a drop in pH. Consequently, pepsin present 
in a reflux episode which leaves the oesophagus can bind to 
the mucosa of the aerodigestive tract, remain inactive but 
native after neutralization by saliva and bicarbonate. The 
bound pepsin can be re-activated by a new reflux event if the 
pH is below 6.0 with resulting tissue damage (19,23). Pepsin 
from refluxate is recognised as a biomarker of reflux as well 
as in tissue damage. In addition to pepsin, bile acids have 
been strongly implicated when present in the refluxate as 
biomarkers of reflux and damaging agents (19,23). However, 
many of the papers dealing with bile acids are using assays 
which do not have the required sensitivity (24-28). 
Diseases associated with reflux identified by 
the presence of pepsin
Over the past ten years or more the presence of pepsin has 
been associated with many diseases of the aerodigestive 
tract including gastro-oesophageal reflux disease (GORD), 
Laryngopharyngeal reflux (LPR), rhinitis and sinusitis, 
vocal fold leucoplakia (VFL), laryngomalacia and several 
lung diseases (28-43) (Table 2). Reflux of gastric contents 
associated diseases have become so prevalent that in the 
recent Incredibles 2 film a new superhero Reflux was born.
What do we need to measure pepsin? Is 
pepsin being measured correctly? Pepsin or 
pepsinogen?
Pepsin is not secreted at proximal sites in the gastrointestinal 
tract. Therefore, it represents a rational and objective 
marker of recent reflux events when detected in biological 
samples from the aerodigestive tract, like saliva and sputum. 
Measurement of pepsin concentration would not provide 
information on whether pepsin detected was active or 
denatured. Due to the characteristic proteolytic action at 
low pH of pepsins, it is also possible to define their activity 
by kinetics which may provide further insights into their 
damaging potential in reflux.
A monoclonal/monospecific polyclonal antibody 
ELISA with a good lowest level of detection (LLOD) and 
sensitivity 1–25 ng/mL (depending on dilution) and an 
adequate supply of human pepsin as a standard are needed. 
If possible, an activity assay for pepsin should also be used 
as the presence of pepsin protein does not indicate it is 
capable of damaging activity. Finally, if pepsin is associated 
with a disease large studies are required to confirm it.
We have isolated pepsin using anion exchange HPLC, 
from human gastric juice obtained at endoscopy. Figure 1 
shows pepsin eluting at 10–15 minutes from the HPLC 
column has a molecular weight just below 37,000. The 
fraction collected between 10–15 minutes also showed 
proteolytic activity at pH 2.2 using an N-terminal plate 
assay (44-46). This is characteristic of human pepsin.
Table 2 Disease associated with reflux and identified by the  
presence of pepsin
Diseases Reference
Laryngopharyngeal reflux (LPR) (28-32)
Gastro-oesophageal reflux (GORD) (33,34)
Otitis media with effusion (OME) (35,36)
Laryngomalacia (37,38)
Vocal fold leucoplakia (associated with LPR) (39,40)
Rhinitis and sinusitis (41)
Lung transplant rejection (42)
Oesophageal atresia (43)
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There are several examples in the literature where these 
criteria are not followed. Iannella et al. (47) investigated 
pepsin in tears of children with LPR and suggested a 
route for pepsin in the refluxate to the pre-corneal film 
via the nasal fossa, inferior meatus, and nasolacrimal duct. 
The problems with this study involves the assay used to 
measure pepsin. It was an ELISA supplied by DRG Inc., 
Germany. However, this company has never had a pepsin 
ELISA only a pepsinogen one. The authors determined 
the LLOD as 2.5 ng/mL and considered the sensitivity as 
a percentage increase over the blank e.g., 2.5 ng/mL gave a 
33.5% increase in absorbance over the blank. It is difficult 
to ascertain the absorbance changes and to know if they 
are in the spectrophotometer’s measurable range. They 
reported pepsin levels in tears between 3.5–5.4 ng/mL in 
4/20 children with LPR, confirmed by 24-hour impedance 
and with non LPR controls having no pepsin. The problem 
with values this small is that serum levels of pepsinogen 
are 50–87 ng/mL (18) and the ELISA used will measure 
pepsinogen.
A study by O’Reilly et al. (36) investigating the role of 
gastric pepsin in the inflammatory cascade of paediatric 
otitis media used a large group of 129 subjects with 50% 
positive for pepsin in the middle ear effusions (glue). The 
authors used a monoclonal antibody supplied by Bio-
Rad Serotec against human pepsin A in a standard ELISA 
with a claimed lower level of sensitivity of 0.1 ng/mL and 
with a cut off for pepsin detection starting at 0.25 ng/mL. 
Alongside this pepsin effusions were assayed for bacterial 
infection and several cytokines. The results demonstrated 
that the presence of pepsin correlated with age younger 
than three years. Pepsin presence was not associated 
with increased bacterial infection, but IL-8 levels were 
significantly associated with bacterial infection levels. The 
treatment for glue ear is to drain the middle ear cleft and 
place a tympanostomy tube in the ear drum. Interestingly 
this study showed that the levels of pepsin were significantly 
associated with IL-8 and the need for second and third 
tubes. This suggests that when reflux persists as identified 
by the presence of pepsin, second and third operations 
would be required. This data suggests a cascade as shown in 
Figure 2 with pepsin causing damage to the middle ear and 
inflammation resulting in increased synthesis and secretion 
of IL-8, a recognised mucin secretagogue (47-49); causing 
an increase in mucin secretion accumulating in the middle 
ear cleft. Again, this study has some problems relating 
to the measurement of pepsin. There is no report of the 
actual pepsin levels. The Bio-Rad Serotec company website 
confirms the antibody is monoclonal and it recognises both 
human pepsinogen 3 and pepsin 3 and that it recognises a 
47,000 molecular weight protein from gastric juice. Pepsin 
has a molecular weight ~35,000 and pepsinogen ~42,000. 
In another study by Gong et al. (39) attempts were made 
to detect pepsin in biopsies from patients with vocal fold 





















Figure 1 Human gastric juice was obtained from volunteers 
undergoing routine gastroscopy. Pepsin was isolated through 
HPLC on an anion exchange column as per the methods of Coyle 
(in 2006) and Jones et al. (in 1993) with slight modification. Sample 
fractions were collected at 0–5, 5–10, 10–15, and 15–30 minutes, 
and run on an SDS-Page (45,46). Arrow indicates pepsin band.
Figure 2 Pepsin mediated cascade in otitis media. This figure was 
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aerodigestive tract (50). This was only a small study with 
26 patients and 20 controls. It used immunohistochemistry 
with a polyclonal pepsin antibody and the results showed a 
significant increase in pepsin staining in VFL, compared to 
the controls suggesting LPR could be a risk factor for the 
development of VFL. It is difficult to assess the validity of 
this paper as there is little information from the supplier, 
Cloud-Clone Corp as to the specificity and cross reactivity 
of the antibody. Luebke et al. (38) carried out a small study 
of 10 laryngomalacia (LM) patients under 3 years old and 
5 age matched control subjects. Pepsin was measured in 
supraglottic lavage samples in the controls and laryngomalacia 
patients and in biopsies from the laryngomalacia patients 
only. The results showed that 8/10 of the laryngomalacia 
subjects had lavage pepsin but none of the controls had. Four 
out of 10 of the LM subject biopsies showed the presence of 
pepsin. If the biopsy was pepsin positive so was the lavage. 
They concluded that refluxed pepsin was implicated as 
having a role in laryngomalacia. This paper used correct 
antibodies and detected pepsin. They measured pepsin using 
SDS PAGE and western blot in biopsies and lavage samples 
using a monoclonal antibody raised to human pepsin A which 
will recognise both pepsin and pepsinogen but as they have 
different molecular weights they could be differentiated on 
western blots. The antibody used in an ELISA to quantitate 
the pepsin levels in the lavages was raised against the 
N-terminus of human pepsin 3b, so it will not be expected to 
recognise human pepsinogen as it has a different N-terminus. 
The authors do not give a LLOD value for the ELISA so 
it is difficult to know if the pepsin values can be reported in 
ng/mL to one decimal point. In addition, they very diligently 
reported significantly higher median pepsin was observed 
in the LM patients compared to the controls in which no 
pepsin was detected. Calvo-Henríquez et al. (32) in 2017 
carried out a systematic review to investigate if pepsin was 
a reliable marker of LPR. They initially included all studies 
up to December 2016 that contained pepsin measurements 
in LPR. 146 studies were found and any studies with no 
controls or a small sample size (less than 20) were excluded. 
This left 12 studies. The methods used to measure pepsin in 
the 12 studies were biopsy immunohistochemistry, western 
blot, and saliva ELISA and Peptest—a lateral flow device 
using monoclonal antibodies. Ten of the twelve studies 
found pepsin was significantly increased in LPR cases versus 
controls (32). The two studies that failed to show a significant 
link could be explained as follow, Komatsu et al. (30) 
measuring pharyngeal biopsies and western blots did not use 
non-symptomatic controls but instead used GORD patients 
as controls. Yadlapati et al. (51) using the Peptest measuring 
salivary pepsin also failed to show a significant increase in 
positive pepsin in LPR compared to controls. This may 
in part be due to the patient group being defined by reflux 
symptom index (RSI) (52), not the most reliable method of 
diagnosis of LPR. However, if pepsin (semi-quantitative) 
concentrations were compared rather than just pepsin 
positivity then significant differences were found between 
laryngeal and oesophageal symptoms and the control groups. 
This systematic review concluded that pepsin could be a 
reliable marker of LPR but optimal sampling time and 
threshold/cut off levels need to be defined. In addressing this 
Klimara et al. (in 2020) (28) investigated the optimum time 
for collection of samples of saliva and nasal lavage as markers 
of LPR. The study used 26 patients tested with 24-hour 
multi-channel intraluminal impedance (MII-pH) and reflux 
finding score (RFS) (53) and RSI to evaluate LPR. The 
control group was 13 subjects defined as reflux absent. Nasal 
lavage samples were collected at tube placement and saliva 
samples collected at different times. Firstly, in the clinic 
before MII-pH probe placement then an hour after each 
meal and on waking the next morning. Pepsin was measured 
with an ELISA using the monoclonal antibody previously 
described in Luebke et al. (38) specific for human pepsin. 
No pepsin was detected in any saliva samples or nasal lavage 
from the control subjects. The results showed that of the 
patients with suspected LPR, 19 out of 26 were confirmed 
by MII-pH and eight of the 19 had pepsin in any collected 
sample with 5 in the morning saliva sample. In addition, 
three of the seven patients negative with MII-pH had pepsin 
in any collected sample and all three of these had pepsin in 
the morning sample. The highest levels of pepsin were found 
in the nasal lavage samples with a mean of 7,662 ng/mL 
which could mean pepsin had accumulated in the nose from 
previous reflux events. The highest levels of salivary pepsin 
were in the morning after waking with a mean of 187 ng/mL 
with much lower values at the other time points. The pepsin 
levels on waking also significantly correlated with MII-pH 
parameters indicating proximal reflux and RSI scores but not 
with RFS. In conclusion if salivary pepsin is to be a useful 
diagnostic tool for LPR the levels should be measured on 
waking or additionally at a time when the patient identifies a 
reflux event.
Over recent years there has been accumulating evidence 
that measurement of pepsin in saliva could make a good 
screening tool in the diagnosis of reflux related diseases 
(28,43,54-60).
However, a paper published in 2019 (61) placed doubt 
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on the usefulness of salivary pepsin in patients with GORD. 
This study used a relatively small study group, 30 GORD 
patients and 20 asymptomatic controls and collected saliva 
samples at different time points when a dual channel pH 
catheter was in place. They compared a commercial lateral 
flow device (Peptest, RD biomed Hull UK) which uses 
pepsin specific monoclonal antibodies with a pepsin ELISA, 
using a monoclonal antibody supplied by Santa Cruz 
(sc365680).
They concluded that Peptest did not identify the patients 
from the controls based on pepsin levels. In addition, the 
ELISA did not show a difference in pepsin levels between 
the patients and the controls. Also, there was no correlation 
between the Peptest and the pepsin ELISA. This paper has 
several flaws. Firstly, the Peptest does measure the major 
human pepsin in gastric juice shown by its reactivity with 
human pepsin of the correct molecular weight. The ELISA 
in Race et al. using an antibody specifically designed as 
a research tool and not for diagnostic purposes. Figure 3 
taken from the Santa Cruz website shows a western blot 
of human stomach tissue extract using the antibody raised 
against a recombinant protein mapping to amino acids 
281–324 near the C terminus of pepsin A (a member of 
the PGI group). Consequently, as pepsinogens and pepsins 
have the same C-terminal it will recognise both. Based on 
Figure 3 the antibody is recognising several components of 
stomach tissue, most if not all are larger than the molecular 
weight of pepsin or pepsinogen (3,5,13-15). This indicates 
a lack of specificity for pepsin. The antibody does recognise 
a recombinant protein containing amino acids 15–388 of 
pepsin A and this is not in dispute, but it is what else it 
recognises that is the pertinent question. This stresses the 
importance of using human pepsin isolated from gastric 
juice to test antibody specificity and to produce standard 
curves.
Secondly the 37% detection of pepsin in the control 
group samples needs to be addressed as other studies 
(28,62) have shown that healthy controls were negative for 
pepsin. In any study involving intubation a control without 
intubation should be carried out to determine if intubation 
causes reflux (63).
Thirdly the authors suggest that the presence of pepsin 
in saliva is not from reflux but from expression of pepsin by 
the tongue. This can be dismissed as the Human Expression 
Atlas lists nine studies on tissue expression of pepsinogen 
and only one reports any in the tongue at levels too low to 
account for the levels detected in saliva (64).
Conclusions
Pepsins in human gastric juice exist as several isoforms 
and pepsin is activated from pepsinogen by simply a fall in 
pH. In terms of proteolytic activity pepsin should not be 
regarded as simply a low pH protease as it has activity close 
to neutral. Pepsin has a key function in the gastric juice as 
an antimicrobial agent via its proteolytic activity, but we 
now know the activation peptides from pepsinogen can also 
act as antimicrobial peptides. Pepsin has the potential to 
be a biomarker of diseases associated with reflux of gastric 
contents. However, it is key to ensure that any assay system 
has the required specificity and sensitivity.
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